Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01091077 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01091077: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT01091077 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01091077, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
Hepatitis C virus when it leaves the cells in the liver is bound to a type of fat. An component of grapefruit could block this fat and thus lower the amount of virus in the blood stream. We propose that treatment with this ingredient, called naringenin, could be used to block this fat and HCV in persons infected with hepatitis C.
Interventions
- DIETARY_SUPPLEMENT Naringenin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01091077
The ClinicalTrials.gov registry entry for NCT01091077 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Naringenin is the first listed.
NCT01091077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01091077 about?
NCT01091077 is a clinical study titled "A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection". Hepatitis C virus when it leaves the cells in the liver is bound to a type of fat. An component of grapefruit could block this fat and thus lower the amount of virus in the blood stream. We propose that treatment with this ingredient, called naringenin, could be used to block this fat and HCV in per...
What is the current status of trial NCT01091077?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2009-06. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01091077?
The interventions under investigation include: Naringenin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01091077?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.